Comparative study of the efficacy and safety of remimazolam and midazolam for general anesthesia in elderly patients: a randomized controlled trial

Abstract Background Elderly patients are a vulnerable group with high perioperative risks. Thus, reducing the duration of anesthesia is important. Remimazolam is a benzodiazepine sedative commonly used for the induction and maintenance of general anesthesia given its rapid induction and rapid recove...

Full description

Saved in:
Bibliographic Details
Main Authors: Yang Wan-jun, Geng Zhi-long, Gao Yuan-yuan, Cui Chao-yuan, Chen Zheng-ze, Tian Zi-wei, Guo Xi-lin, Zhang Ya-nan, Wang Lu, Huo Rui, Ma Chen-wei, Niu Jing
Format: Article
Language:English
Published: BMC 2025-05-01
Series:Perioperative Medicine
Subjects:
Online Access:https://doi.org/10.1186/s13741-025-00525-9
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849311980125421568
author Yang Wan-jun
Geng Zhi-long
Gao Yuan-yuan
Cui Chao-yuan
Chen Zheng-ze
Tian Zi-wei
Guo Xi-lin
Zhang Ya-nan
Wang Lu
Huo Rui
Ma Chen-wei
Niu Jing
author_facet Yang Wan-jun
Geng Zhi-long
Gao Yuan-yuan
Cui Chao-yuan
Chen Zheng-ze
Tian Zi-wei
Guo Xi-lin
Zhang Ya-nan
Wang Lu
Huo Rui
Ma Chen-wei
Niu Jing
author_sort Yang Wan-jun
collection DOAJ
description Abstract Background Elderly patients are a vulnerable group with high perioperative risks. Thus, reducing the duration of anesthesia is important. Remimazolam is a benzodiazepine sedative commonly used for the induction and maintenance of general anesthesia given its rapid induction and rapid recovery. Most reports have focused on nonelderly patients. Aim To compare the time to loss of consciousness, length of PACU stay and incidence of adverse events in patients older than 65 years who received remimazolam for general anesthesia with those of patients who received midazolam. Methods This study was conducted at a university hospital between February 2022 and March 2023. We included 100 patients aged 65 years or older who were scheduled for surgery under general anesthesia. Patients were divided into 2 groups, namely, the midazolam group and the remimazolam group, with 50 patients in each group. The primary outcome was the time to loss of consciousness. The secondary outcomes included the time to extubation and length of PACU stay. We also recorded the percentage of flumazenil used and incidence of adverse events. Results Clinical data from 96 patients who were scheduled for surgery under general anesthesia were included in the final analysis, with 46 patients in the remimazolam group and 50 patients in the midazolam group. The time to loss of consciousness was 304 (222, 330) s in the remimazolam group and 95 (67, 25) s in the midazolam group, and the difference was significant (p = 0.000). The time to extubation was 24.93 ± 11.617 min in the remimazolam group and 34.88 ± 19.740 min in the midazolam group, revealing a significant difference (p = 0.003). The length of PACU stay was 55 (48, 64) min in the remimazolam group and 65 (55, 85) min in the midazolam group, and the difference was significant (p = 0.001). The percentage of flumazenil used was 6% in the remimazolam group and 20% in the midazolam group, and the difference was significant (p = 0.003). Conclusion General anesthesia with remimazolam has been shown to be effective and safe for surgery in elderly patients. The time to extubation was significantly shorter, length of PACU stay was shorter, and percentage of flumazenil used was lower in the remimazolam group than in the midazolam group.
format Article
id doaj-art-b5917bcd56a8474ebc14f174739f41ba
institution Kabale University
issn 2047-0525
language English
publishDate 2025-05-01
publisher BMC
record_format Article
series Perioperative Medicine
spelling doaj-art-b5917bcd56a8474ebc14f174739f41ba2025-08-20T03:53:13ZengBMCPerioperative Medicine2047-05252025-05-0114111010.1186/s13741-025-00525-9Comparative study of the efficacy and safety of remimazolam and midazolam for general anesthesia in elderly patients: a randomized controlled trialYang Wan-jun0Geng Zhi-long1Gao Yuan-yuan2Cui Chao-yuan3Chen Zheng-ze4Tian Zi-wei5Guo Xi-lin6Zhang Ya-nan7Wang Lu8Huo Rui9Ma Chen-wei10Niu Jing11Department of Anesthesiology, The Second Affiliated Hospital of Xi’an Medical UniversityDepartment of Anesthesiology, The Second Affiliated Hospital of Air Force Medical UniversityDepartment of Anesthesiology, The Second Affiliated Hospital of Xi’an Medical UniversityDepartment of Anesthesiology, The Second Affiliated Hospital of Xi’an Medical UniversityDepartment of Anesthesiology, The Second Affiliated Hospital of Xi’an Medical UniversityDepartment of Anesthesiology, The Second Affiliated Hospital of Xi’an Medical UniversityDepartment of Anesthesiology, The Second Affiliated Hospital of Xi’an Medical UniversityDepartment of Anesthesiology, The Second Affiliated Hospital of Xi’an Medical UniversityDepartment of Anesthesiology, The Second Affiliated Hospital of Xi’an Medical UniversityDepartment of Anesthesiology, The Second Affiliated Hospital of Xi’an Medical UniversityDepartment of Anesthesiology, The Second Affiliated Hospital of Xi’an Medical UniversityDepartment of Anesthesiology, The Second Affiliated Hospital of Air Force Medical UniversityAbstract Background Elderly patients are a vulnerable group with high perioperative risks. Thus, reducing the duration of anesthesia is important. Remimazolam is a benzodiazepine sedative commonly used for the induction and maintenance of general anesthesia given its rapid induction and rapid recovery. Most reports have focused on nonelderly patients. Aim To compare the time to loss of consciousness, length of PACU stay and incidence of adverse events in patients older than 65 years who received remimazolam for general anesthesia with those of patients who received midazolam. Methods This study was conducted at a university hospital between February 2022 and March 2023. We included 100 patients aged 65 years or older who were scheduled for surgery under general anesthesia. Patients were divided into 2 groups, namely, the midazolam group and the remimazolam group, with 50 patients in each group. The primary outcome was the time to loss of consciousness. The secondary outcomes included the time to extubation and length of PACU stay. We also recorded the percentage of flumazenil used and incidence of adverse events. Results Clinical data from 96 patients who were scheduled for surgery under general anesthesia were included in the final analysis, with 46 patients in the remimazolam group and 50 patients in the midazolam group. The time to loss of consciousness was 304 (222, 330) s in the remimazolam group and 95 (67, 25) s in the midazolam group, and the difference was significant (p = 0.000). The time to extubation was 24.93 ± 11.617 min in the remimazolam group and 34.88 ± 19.740 min in the midazolam group, revealing a significant difference (p = 0.003). The length of PACU stay was 55 (48, 64) min in the remimazolam group and 65 (55, 85) min in the midazolam group, and the difference was significant (p = 0.001). The percentage of flumazenil used was 6% in the remimazolam group and 20% in the midazolam group, and the difference was significant (p = 0.003). Conclusion General anesthesia with remimazolam has been shown to be effective and safe for surgery in elderly patients. The time to extubation was significantly shorter, length of PACU stay was shorter, and percentage of flumazenil used was lower in the remimazolam group than in the midazolam group.https://doi.org/10.1186/s13741-025-00525-9RemimazolamElderly patientsMidazolam
spellingShingle Yang Wan-jun
Geng Zhi-long
Gao Yuan-yuan
Cui Chao-yuan
Chen Zheng-ze
Tian Zi-wei
Guo Xi-lin
Zhang Ya-nan
Wang Lu
Huo Rui
Ma Chen-wei
Niu Jing
Comparative study of the efficacy and safety of remimazolam and midazolam for general anesthesia in elderly patients: a randomized controlled trial
Perioperative Medicine
Remimazolam
Elderly patients
Midazolam
title Comparative study of the efficacy and safety of remimazolam and midazolam for general anesthesia in elderly patients: a randomized controlled trial
title_full Comparative study of the efficacy and safety of remimazolam and midazolam for general anesthesia in elderly patients: a randomized controlled trial
title_fullStr Comparative study of the efficacy and safety of remimazolam and midazolam for general anesthesia in elderly patients: a randomized controlled trial
title_full_unstemmed Comparative study of the efficacy and safety of remimazolam and midazolam for general anesthesia in elderly patients: a randomized controlled trial
title_short Comparative study of the efficacy and safety of remimazolam and midazolam for general anesthesia in elderly patients: a randomized controlled trial
title_sort comparative study of the efficacy and safety of remimazolam and midazolam for general anesthesia in elderly patients a randomized controlled trial
topic Remimazolam
Elderly patients
Midazolam
url https://doi.org/10.1186/s13741-025-00525-9
work_keys_str_mv AT yangwanjun comparativestudyoftheefficacyandsafetyofremimazolamandmidazolamforgeneralanesthesiainelderlypatientsarandomizedcontrolledtrial
AT gengzhilong comparativestudyoftheefficacyandsafetyofremimazolamandmidazolamforgeneralanesthesiainelderlypatientsarandomizedcontrolledtrial
AT gaoyuanyuan comparativestudyoftheefficacyandsafetyofremimazolamandmidazolamforgeneralanesthesiainelderlypatientsarandomizedcontrolledtrial
AT cuichaoyuan comparativestudyoftheefficacyandsafetyofremimazolamandmidazolamforgeneralanesthesiainelderlypatientsarandomizedcontrolledtrial
AT chenzhengze comparativestudyoftheefficacyandsafetyofremimazolamandmidazolamforgeneralanesthesiainelderlypatientsarandomizedcontrolledtrial
AT tianziwei comparativestudyoftheefficacyandsafetyofremimazolamandmidazolamforgeneralanesthesiainelderlypatientsarandomizedcontrolledtrial
AT guoxilin comparativestudyoftheefficacyandsafetyofremimazolamandmidazolamforgeneralanesthesiainelderlypatientsarandomizedcontrolledtrial
AT zhangyanan comparativestudyoftheefficacyandsafetyofremimazolamandmidazolamforgeneralanesthesiainelderlypatientsarandomizedcontrolledtrial
AT wanglu comparativestudyoftheefficacyandsafetyofremimazolamandmidazolamforgeneralanesthesiainelderlypatientsarandomizedcontrolledtrial
AT huorui comparativestudyoftheefficacyandsafetyofremimazolamandmidazolamforgeneralanesthesiainelderlypatientsarandomizedcontrolledtrial
AT machenwei comparativestudyoftheefficacyandsafetyofremimazolamandmidazolamforgeneralanesthesiainelderlypatientsarandomizedcontrolledtrial
AT niujing comparativestudyoftheefficacyandsafetyofremimazolamandmidazolamforgeneralanesthesiainelderlypatientsarandomizedcontrolledtrial